
Karius is a clinical metagenomics company that leverages genomics and AI to advance infectious disease diagnostics. Founded in 2014 and headquartered in Redwood City, California, Karius operates a CLIA-certified and CAP-accredited laboratory performing high-complexity clinical testing. The company provides unique genomic insights by detecting microbial cell-free DNA circulating in the body from pathogens, enabling rapid and precise diagnosis to assist physicians in treatment decisions. Karius offers products such as Karius Spectrum and Karius Focus | BAL, serving leading hospitals and transplant centers across the US. Their proprietary AI and reference genome databases continuously improve diagnostic accuracy, positioning Karius as a leader in infectious disease diagnostics with a vision to eliminate infectious disease as a major health threat.

Karius is a clinical metagenomics company that leverages genomics and AI to advance infectious disease diagnostics. Founded in 2014 and headquartered in Redwood City, California, Karius operates a CLIA-certified and CAP-accredited laboratory performing high-complexity clinical testing. The company provides unique genomic insights by detecting microbial cell-free DNA circulating in the body from pathogens, enabling rapid and precise diagnosis to assist physicians in treatment decisions. Karius offers products such as Karius Spectrum and Karius Focus | BAL, serving leading hospitals and transplant centers across the US. Their proprietary AI and reference genome databases continuously improve diagnostic accuracy, positioning Karius as a leader in infectious disease diagnostics with a vision to eliminate infectious disease as a major health threat.
Founded: 2014
Headquarters: Redwood City, California
Core product: Karius Test — microbial cell-free DNA liquid biopsy for infectious-disease diagnosis
Laboratory: CLIA-certified and CAP-accredited high-complexity clinical laboratory
Recent financing: Series C announced May 2, 2024 ($100M)
Infectious disease diagnostics and microbial detection using genomic sequencing and AI.
2014
Biotechnology Research
100000000
Series C announced May 2, 2024
165000000
Large financing announced February 24, 2020
“Backed by multiple prominent life-sciences and venture investors including Khosla Ventures, 5AM Ventures, Gilde Healthcare, SoftBank Vision Fund, General Catalyst, HBM Healthcare Investments, Khosla Ventures, Lightspeed Venture Partners, Tencent, and others”